Recombinant Activated Factor VII as a Second Line Treatment for Postpartum Hemorrhage
Open Access
- 30 November 2017
- journal article
- Published by The Korean Society of Critical Care Medicine in Acute and Critical Care
- Vol. 32 (4) , 333-339
Abstract
Severe or massive postpartum hemorrhage (PPH) has remained a leading cause of maternal mortality for decades across the world and it results in critical obstetric complications. Recombinant activated factor VII (rFVIIa) has emerged as a gold standard adjunctive hemostatic agent for the treatment of life-threatening PPH refractory to conventional therapies although it remains off-licensed for use in PPH. We studied the effects of rFVIIa on coagulopathy, transfusion volume, prognosis, severity change in Korean PPH patients. A retrospective review of medical records between December 2008 and March 2011 indicating use of rFVIIa in severe PPH was performed. We compared age, rFVIIa treatment, transfusion volume, and Sequential Organ Failure Assessment (SOFA) score at the time of arrival in the emergency department and after 24 hours for patients whose SOFA score was 8 points or higher. Fifteen women with SOFA score of 8 and above participated in this study and eight received rFVIIa administration whereas seven did not. Patients' mean age was 31.7 ± 7.5 years. There was no statistically significant difference in initial and post-24 hours SOFA scores between patients administered rFVIIa or not. The change in SOFA score between initial presentation and after 24 hours was significantly reduced after rFVIIa administration (P = 0.016). This analysis aimed to support that the administration of rFVIIa can reduce the severity of life-threatening PPH in patients. A rapid decision regarding the administration of rFVIIa is needed for a more favorable outcome in severe PPH patients for whom there is no effective standard treatment.Keywords
Funding Information
- Pusan National University
This publication has 15 references indexed in Scilit:
- Prognostic evaluation of severe sepsis and septic shock: Procalcitonin clearance vs Δ Sequential Organ Failure AssessmentJournal of Critical Care, 2015
- Global causes of maternal death: a WHO systematic analysisThe Lancet Global Health, 2014
- The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation*Critical Care Medicine, 2009
- Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhageAustralian and New Zealand Journal of Obstetrics and Gynaecology, 2008
- Use of Recombinant Activated Factor VII in Primary Postpartum HemorrhageObstetrics & Gynecology, 2007
- Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspectiveCritical Care, 2006
- Primary postpartum haemorrhage in an Australian tertiary hospital: a case‐control studyAustralian and New Zealand Journal of Obstetrics and Gynaecology, 2005
- Serial Evaluation of the SOFA Score to Predict Outcome in Critically Ill PatientsJAMA, 2001
- Successful treatment of severe intra‐abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VIIBritish Journal of Haematology, 2001
- Emergency Postpartum Hysterectomy in Obstetric PracticeJournal of Obstetrics and Gynaecology Research, 2000